[Bacteriologic, clinical and kinetic evaluation of cefmenoxime (SCE 1365) in the treatment of 68 cases of septicemia. A multicenter trial].
Cefmenoxime (SCE 1365), a new broad-spectrum, third generation cephalosporin was used in the treatment of 68 patients with bacteremia. Cefmenoxime was given as monotherapy to 63 patients in a mean daily dosage of 3 g (range: 1 to 6 g). 63 successes were recorded. Results were inconclusive in the remaining five cases. General and biological tolerance of cefmenoxime was excellent.
D000328:Adult; D000368:Aged; D001770:Blood Bactericidal Activity; D015281:Cefmenoxime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000188:drug therapy* / Q000382:microbiology
D015281:Cefmenoxime; D002439:Cefotaxime
Evaluation bactériologique, clinique et cinétique de la cefménoxime (SCE 1365) dans le traitement de soixante-huit septicemies. Essai multicentrique.